TY - JOUR
KW - Cost-Benefit Analysis
KW - Delayed-Action Preparations/therapeutic use
KW - Humans
KW - Injections, Intramuscular
KW - Naltrexone/therapeutic use
KW - Narcotic Antagonists/therapeutic use
KW - Opioid-Related Disorders/drug therapy
KW - Retrospective Studies
KW - United States
KW - buprenorphine-naloxone
KW - cost-effectiveness
KW - Efficiency
KW - Extended-release naltrexone
KW - Induction
KW - opioid detoxification
KW - opioid use disorder
AU - S. M. Murphy
AU - P. J. Jeng
AU - K. E. McCollister
AU - J. A. Leff
AU - A. Jalali
AU - M. Shulman
AU - J. D. Lee
AU - E. V. Nunes
AU - P. Novo
AU - J. Rotrosen
AU - B. R. Schackman
A1 - 
AD - Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.; New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, USA.; Department of Population Health, New York University School of Medicine, New York, NY, USA.; New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, USA.; Department of Psychiatry, New York University School of Medicine, New York, NY, USA.; Department of Psychiatry, New York University School of Medicine, New York, NY, USA.; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
BT - Addiction (Abingdon, England)
C5 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
CP - 12
DO - 10.1111/add.15531
IS - 12
JF - Addiction (Abingdon, England)
LA - eng
M1 - Journal Article
PB - Society for the Study of Addiction
PY - 2021
SN - 1360-0443; 0965-2140; 0965-2140
SP - 3444
EP - 3453
EP - 
T1 - Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis
T2 - Addiction (Abingdon, England)
TI - Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis
U1 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
U2 - 33950535
U3 - 10.1111/add.15531
VL - 116
VO - 1360-0443; 0965-2140; 0965-2140
Y1 - 2021
Y2 - Dec
ER -